Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years and are deemed high risk. Here we analyze structural variants from 795 newly-diagnosed patients as part of the CoMMpass study. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478743/
https://www.ncbi.nlm.nih.gov/pubmed/31015454
http://dx.doi.org/10.1038/s41467-019-09555-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478743/
https://www.ncbi.nlm.nih.gov/pubmed/31015454
http://dx.doi.org/10.1038/s41467-019-09555-6

Ejemplares similares